CABOMETYX

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug CABOMETYX contains one active pharmaceutical ingredient (API):

1	Cabozantinib UNII DR7ST46X58 - CABOZANTINIB S-MALATE
	Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer. Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. In addition, cabozantinib inhibits other tyrosine kinases including the GAS6 receptor (AXL), RET, ROS1, TYRO3, MER, the stem cell factor receptor (KIT), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2.
	Read more about Cabozantinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CABOMETYX Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX07		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11360X, 11367G, 11368H, 11369J, 11371L, 11374P
BR	Câmara de Regulação do Mercado de Medicamentos	539219010001002, 539219010001102, 539219010001202
CA	Health Products and Food Branch	02480824, 02480832, 02480840
EE	Ravimiamet	1728840, 1728862, 1728884
ES	Centro de información online de medicamentos de la AEMPS	1161136002, 1161136004, 1161136006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	111502, 118175, 126777
FR	Base de données publique des médicaments	66607321, 68164846, 69990857
GB	Medicines & Healthcare Products Regulatory Agency	336229, 336232, 336329, 392259, 392276, 392343
HK	Department of Health Drug Office	65654, 65655, 65656
IE	Health Products Regulatory Authority	88840, 88841, 88842
IL	מִשְׂרַד הַבְּרִיאוּת	8112, 8113, 8114
JP	医薬品医療機器総合機構	4291064F1020, 4291064F2026
LT	Valstybinė vaistų kontrolės tarnyba	1081053, 1081055, 1081057
NL	Z-Index G-Standaard, PRK	135895, 135909, 135917
NZ	Medicines and Medical Devices Safety Authority	21186, 21187, 21188
PL	Rejestru Produktów Leczniczych	100377658, 100377664, 100377693
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64527001, W64528001, W64529001
SG	Health Sciences Authority	15606P, 15607P, 15608P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699783090449, 8699783090456, 8699783090463
US	FDA, National Drug Code	42388-023, 42388-024, 42388-025